



ASX ANNOUNCEMENT

10 February 2014

## ***Cynata Partners With Leading Biologic Product Manufacturer***

Cynata Therapeutics Ltd (ASX:CYP), announced today that it has signed a manufacturing agreement with Waisman Biomanufacturing ("Waisman") under which Waisman will undertake manufacturing process development, scale-up and clinical-grade manufacture of Cynata's proprietary Cymerus™ off-the-shelf stem cell product. This will enable Cynata to rapidly advance its next generation stem cell technology towards clinical trials and commercial transactions.

"We are very pleased to be partnering with Waisman Biomanufacturing given their extensive experience in manufacturing process development and cGMP production of biologic products for human clinical trials", said Dr Ross Macdonald, Chief Executive Officer of Cynata Therapeutics. "Our pre-clinical studies have shown great promise for bringing the Cymerus™ technology into the clinic and eventually to the market. The next step is the establishment of this relationship to demonstrate the commercial scalability of Cymerus™ to address substantial market opportunities."

With its proximity to the renowned centers of stem cell discovery and research in Madison, Wisconsin, including the laboratories of Cynata co-founder Associate Professor Igor Slukvin, Waisman is very well placed to undertake this program. Waisman specialises in translating scientific discoveries for early stage clinical trials by developing manufacturing and quality control processes in conjunction with product development and regulatory support. "We are very excited to be working with Dr Slukvin and Cynata to advance this unique technology to quickly and efficiently produce this Cymerus™ product for therapeutic use in clinical trials," said Dr Derek Hei, Director of Waisman Biomanufacturing.

The Cymerus™ technology includes proprietary methods of manufacture of stem cell therapeutic products that are believed to provide key advantages over the current generation of multi-donor dependent manufacturing methods.

**Media contacts:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)

### **About Cynata Therapeutics (ASX:CYP)**

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.